TheStreet's Adam Feuerstein rated Gilead Science's [1] second quarter numbers "uninspiring," with strong top-line results and a disappointment in earnings. As one of the few profitable biotechs in the market, though, the analysts concluded that a record of strong results would likely entice investors willing to overlook any short-term weakness. Report [2]
Links:
[1] http://www.fiercebiotech.com/special-reports/gilead-sciences-big-biotechs-stock-report
[2] http://www.thestreet.com/s/post-earnings-gilead-offers-buying-opportunity/newsanalysis/biotech/10427249.html?puc=googlen&cm_ven=GOOGLEN&cm_cat=FREE&cm_ite=NA